BE2017C067I2 - - Google Patents

Download PDF

Info

Publication number
BE2017C067I2
BE2017C067I2 BE2017C067C BE2017C067C BE2017C067I2 BE 2017C067 I2 BE2017C067 I2 BE 2017C067I2 BE 2017C067 C BE2017C067 C BE 2017C067C BE 2017C067 C BE2017C067 C BE 2017C067C BE 2017C067 I2 BE2017C067 I2 BE 2017C067I2
Authority
BE
Belgium
Prior art keywords
warm
treatment
allergy
mastocytosis
angioedema
Prior art date
Application number
BE2017C067C
Other languages
French (fr)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33539193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2017C067(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BE2017C067I2 publication Critical patent/BE2017C067I2/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

This application relates to the use of staurosporines derivatives for the curative, palliative or prophylactic treatment of allergic rhinitis, allergic dermatitis, drug allergy or food allergy, angioedema, urticaria, sudden infant death syndrome, bronchopulmonary aspergillosis, multiple sclerosis, or mastocytosis; and to a method of treatment of warm-blooded animals in which a therapeutically effective dose of a compound of a Staurosporine Derivative is administered to a warm-blooded animal suffering from one of the diseases or conditions mentioned above.
BE2017C067C 2003-06-18 2017-12-19 BE2017C067I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47957503P 2003-06-18 2003-06-18
PCT/EP2004/006562 WO2004112794A2 (en) 2003-06-18 2004-06-17 New pharmaceutical uses of staurosporine derivatives
EP04740016A EP1638574B1 (en) 2003-06-18 2004-06-17 New pharmaceutical uses of staurosporine derivatives

Publications (1)

Publication Number Publication Date
BE2017C067I2 true BE2017C067I2 (en) 2023-08-09

Family

ID=33539193

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2017C067C BE2017C067I2 (en) 2003-06-18 2017-12-19

Country Status (23)

Country Link
US (2) US8575146B2 (en)
EP (1) EP1638574B1 (en)
JP (2) JP5057780B2 (en)
CN (2) CN101164539A (en)
AT (1) ATE464052T1 (en)
AU (1) AU2004248909B2 (en)
BE (1) BE2017C067I2 (en)
BR (1) BRPI0411563B8 (en)
CA (2) CA2785950A1 (en)
CY (2) CY1110179T1 (en)
DE (1) DE602004026578D1 (en)
DK (1) DK1638574T3 (en)
ES (1) ES2344700T3 (en)
FR (1) FR17C1063I2 (en)
HU (1) HUS000503I2 (en)
LU (1) LUC00055I9 (en)
MX (1) MXPA05013722A (en)
NL (1) NL300917I2 (en)
PL (1) PL1638574T3 (en)
PT (1) PT1638574E (en)
SI (1) SI1638574T1 (en)
TW (1) TWI324604B (en)
WO (1) WO2004112794A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
JP4762150B2 (en) 2003-11-18 2011-08-31 ノバルティス アーゲー KIT mutant inhibitors
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
WO2006020145A2 (en) * 2004-07-19 2006-02-23 The Johns Hopkins University Flt3 inhibitors for immune suppression
MX2007001155A (en) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Methods, systems, and computer program products for providing presence gateway functionality in a telecommunications network.
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
AU2006242311B2 (en) * 2005-05-02 2010-03-04 Novartis Ag Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis
PT1909837E (en) * 2005-07-20 2010-07-07 Novartis Ag Compositions for treatment of systemic mastocytosis
KR20080067654A (en) * 2005-11-14 2008-07-21 유니베르시태트 취리히 Staurosporin derivative for use in alveolar rhabdomyosarcoma
WO2009092442A1 (en) * 2008-01-23 2009-07-30 Universidad De Barcelona Treatment of portal hypertension and related conditions by combined inhibition of the vegf and pdgf signalling pathways
US8802099B2 (en) 2010-11-10 2014-08-12 National Jewish Health Methods to treat allergic conditions
JP2022508055A (en) 2018-11-01 2022-01-19 サイロス ファーマシューティカルズ, インコーポレイテッド Inhibitor of cyclin-dependent kinase 7 (CDK7)
US11325978B2 (en) * 2018-11-06 2022-05-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for treating beta-globinopathies
US11839619B2 (en) * 2019-09-16 2023-12-12 The Regents Of The University Of California Methods for treatment of pediatric systemic mastocytosis
KR102805013B1 (en) * 2022-03-15 2025-05-09 국립해양생물자원관 Pharmaceutical composition for preventing or treating nasal polyps comprising streptomyces sp. SNC087 or staurosporine isolated therefrom as an active ingredient

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639455A (en) * 1984-10-02 1987-01-27 Key Pharmaceuticals, Inc. Means of aiding in the prevention of sudden infant death syndrome
JPH0826037B2 (en) 1987-01-22 1996-03-13 協和醗酵工業株式会社 Derivatives of physiologically active substance K-252
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
CA2046801C (en) 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
DE122007000073I1 (en) * 1991-05-09 2008-01-31 Neurim Pharma 1991 Melatonin-containing medicines
AR004480A1 (en) 1995-04-06 1998-12-16 Amico Derin C D ASCOMICINE COMPOUNDS HAVING ANTI-INFLAMMATORY ACTIVITY, PROCEDURE TO PREPARE THEM, USE OF SUCH COMPOUNDS TO PREPARE PHARMACEUTICAL AGENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM
NZ333441A (en) * 1996-06-25 1999-05-28 Cephalon Inc Use of k-252a derivatives for the treatment of peripheral or central nerve disorders, and cytokine overproduction
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
AU4423799A (en) * 1998-06-04 1999-12-20 Cornell Research Foundation Inc. Methods and agents for modulating the immune response and inflammation involvingmonocyte and dendritic cell membrane proteins
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
AU2002227371B2 (en) * 2000-12-08 2007-05-10 Ortho-Mcneil Pharmaceutical, Inc. Macroheterocylic compounds useful as kinase inhibitors
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
EP1471907B1 (en) * 2001-06-29 2008-07-16 AB Science Use of c-kit inhibitors for treating autoimmune diseases
PT1441737E (en) * 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
CA2522712A1 (en) * 2003-04-18 2004-10-28 Kyowa Hakko Kogyo Co., Ltd. Nerve regenerating drug
WO2004093910A1 (en) * 2003-04-22 2004-11-04 Astellas Pharma Inc. REMEDY FOR CEREBRAL NEURODEGENERATIVE DISEASES USING PPARδ AGONIST
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
JP4762150B2 (en) 2003-11-18 2011-08-31 ノバルティス アーゲー KIT mutant inhibitors

Also Published As

Publication number Publication date
LUC00055I2 (en) 2018-02-21
BRPI0411563B8 (en) 2021-05-25
EP1638574A2 (en) 2006-03-29
JP5057780B2 (en) 2012-10-24
US20070299049A1 (en) 2007-12-27
LUC00055I9 (en) 2022-11-09
BRPI0411563B1 (en) 2019-09-24
TWI324604B (en) 2010-05-11
EP1638574B1 (en) 2010-04-14
HUS1700053I1 (en) 2018-01-29
TW200512213A (en) 2005-04-01
US20130289018A1 (en) 2013-10-31
LUC00055I1 (en) 2017-12-14
ATE464052T1 (en) 2010-04-15
PL1638574T3 (en) 2010-09-30
CN100457111C (en) 2009-02-04
CY2017048I1 (en) 2018-09-05
BRPI0411563A (en) 2006-08-01
JP2006527727A (en) 2006-12-07
CN101164539A (en) 2008-04-23
CY2017048I2 (en) 2018-09-05
CN1805749A (en) 2006-07-19
NL300917I1 (en) 2017-12-12
WO2004112794A3 (en) 2005-06-16
AU2004248909A1 (en) 2004-12-29
CY1110179T1 (en) 2015-01-14
US8575146B2 (en) 2013-11-05
NL300917I2 (en) 2018-01-09
SI1638574T1 (en) 2010-08-31
MXPA05013722A (en) 2006-03-08
DE602004026578D1 (en) 2010-05-27
PT1638574E (en) 2010-07-14
HUS000503I2 (en) 2021-03-29
DK1638574T3 (en) 2010-08-02
ES2344700T3 (en) 2010-09-03
WO2004112794A2 (en) 2004-12-29
CA2785950A1 (en) 2004-12-29
HK1095519A1 (en) 2007-05-11
FR17C1063I2 (en) 2019-05-03
CA2527703C (en) 2012-10-23
FR17C1063I1 (en) 2018-02-16
AU2004248909B2 (en) 2008-05-08
CA2527703A1 (en) 2004-12-29
JP2012144572A (en) 2012-08-02

Similar Documents

Publication Publication Date Title
FR17C1063I1 (en)
DK1611088T3 (en) Hydroxymates as therapeutic agents
EA201390353A1 (en) DERIVATIVE PYRAZOLOHINOLINA
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
EA200970595A1 (en) DERIVATIVES OF SUBSTITUTED INDAZOLS ACTIVE AS KINAZ INHIBITORS
EA200971053A1 (en) METHODS OF TREATMENT OF THE LEAD ULCERS
ATE411022T1 (en) PYRIDYLPYRROLE DERIVATIVES AS EFFECTIVE KINASE INHIBITORS
ATE520668T1 (en) SIGMARECEPTOR INHIBITORS
DE602004004665D1 (en) Acetylenderivate als inhibitoren von histondeacetylase
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
NO20070113L (en) Opioids for the treatment of restless legs syndrome
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
GB2427405A (en) Novel hydroxamates as therapeutic agents
WO2000076500A8 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
TH401002069A (en) New uses of the sternosporine derivative
SE0103539D0 (en) New Use